Source: http://www.praktikosinstitute.org/health-research/prostate-cancer-alternative-treatment/
Timestamp: 2019-04-19 18:23:29+00:00

Document:
Lin, Y. H., K. K. Chen, and J. H. Chiu. “Coprescription of Chinese Herbal Medicine and Western Medications among Prostate Cancer Patients: A Population-Based Study in Taiwan.” [In eng]. Evid Based Complement Alternat Med 2012 (2012): 147015.
Fang, F., J. L. Kasperzyk, I. Shui, W. Hendrickson, B. W. Hollis, K. Fall, J. Ma, et al. “Prediagnostic Plasma Vitamin D Metabolites and Mortality among Patients with Prostate Cancer.” [In eng]. PLoS One 6, no. 4 (2011): e18625.
Sukumaran, S., K. B. Pittman, W. K. Patterson, J. Dickson, S. Yeend, A. Townsend, V. Broadbridge, and T. J. Price. “A Phase I Study to Determine the Safety, Tolerability and Maximum Tolerated Dose of Green-Lipped Mussel (Perna Canaliculus) Lipid Extract, in Patients with Advanced Prostate and Breast Cancer.” [In eng]. Ann Oncol 21, no. 5 (May 2010): 1089-93.
Flaig, T. W., A. Barqawi, G. Miller, M. Kane, C. Zeng, E. D. Crawford, and L. M. Glode. “A Phase Ii Trial of Dexamethasone, Vitamin D, and Carboplatin in Patients with Hormone-Refractory Prostate Cancer.” [In eng]. Cancer 107, no. 2 (Jul 15 2006): 266-74.
Oh, W. K., D. J. George, K. Hackmann, J. Manola, and P. W. Kantoff. “Activity of the Herbal Combination, Pc-Spes, in the Treatment of Patients with Androgen-Independent Prostate Cancer.” [In eng]. Urology 57, no. 1 (Jan 2001): 122-6.
Abdollah, F., M. Sun, R. Thuret, C. Jeldres, Z. Tian, A. Briganti, S. F. Shariat, et al. “A Competing-Risks Analysis of Survival after Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006.” [In eng]. Eur Urol 59, no. 1 (Jan 2011): 88-95.
Viswanathan, L., and R. A. Vigersky. “The Effect of Herbal Medications on Thyroid Hormone Economy and Estrogen-Sensitive Hepatic Proteins in a Patient with Prostate Cancer.” [In eng]. Arch Intern Med 172, no. 1 (Jan 9 2012): 58-60.
Small, E. J., M. W. Frohlich, R. Bok, K. Shinohara, G. Grossfeld, Z. Rozenblat, W. K. Kelly, M. Corry, and D. M. Reese. “Prospective Trial of the Herbal Supplement Pc-Spes in Patients with Progressive Prostate Cancer.” [In eng]. J Clin Oncol 18, no. 21 (Nov 1 2000): 3595-603.
Oh, W. K., P. W. Kantoff, V. Weinberg, G. Jones, B. I. Rini, M. K. Derynck, R. Bok, et al. “Prospective, Multicenter, Randomized Phase Ii Trial of the Herbal Supplement, Pc-Spes, and Diethylstilbestrol in Patients with Androgen-Independent Prostate Cancer.” [In eng]. J Clin Oncol 22, no. 18 (Sep 15 2004): 3705-12.
Trace elements and vitamin E status in Nigerian patients with prostate cancer.
Adaramoye, O. A., O. Akinloye, and I. K. Olatunji. “Trace Elements and Vitamin E Status in Nigerian Patients with Prostate Cancer.” [In eng]. Afr Health Sci 10, no. 1 (Mar 2010): 2-8.
Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength.
Van Veldhuizen, P. J., S. A. Taylor, S. Williamson, and B. M. Drees. “Treatment of Vitamin D Deficiency in Patients with Metastatic Prostate Cancer May Improve Bone Pain and Muscle Strength.” [In eng]. J Urol 163, no. 1 (Jan 2000): 187-90.
Duconge, J., J. R. Miranda-Massari, M. J. Gonzalez, P. R. Taylor, H. D. Riordan, N. H. Riordan, J. J. Casciari, and K. Alliston. “Vitamin C Pharmacokinetics after Continuous Infusion in a Patient with Prostate Cancer.” [In eng]. Ann Pharmacother 41, no. 6 (Jun 2007): 1082-3.
Choo, R., T. Woo, R. Veith and M. Jamieson. “A pilot study: potential role of nutrient vitamin D in prostate cancer patients with rising PSA after definitive therapy.” [In eng]. EJC Supplements 3, no. 2, Suppl.S (Oct 2005): 250.
Trump, D. L., M. K. Chadha, A. Y. Sunga, M. G. Fakih, U. Ashraf, C. G. Silliman, B. W. Hollis, et al. “Vitamin D Deficiency and Insufficiency among Patients with Prostate Cancer.” [In eng]. BJU Int 104, no. 7 (Oct 2009): 909-14.
Choo, C. S., A. Mamedov, M. Chung, R. Choo, A. Kiss, and C. Danjoux. “Vitamin D Insufficiency Is Common in Patients with Nonmetastatic Prostate Cancer.” [In eng]. Nutr Res 31, no. 1 (Jan 2011): 21-6.
Breen, T. L., and E. Shane. “Prolonged Hypocalcemia after Treatment with Zoledronic Acid in a Patient with Prostate Cancer and Vitamin D Deficiency.” [In eng]. J Clin Oncol 22, no. 8 (Apr 15 2004): 1531-2.
Brausi, M., G. De Luca and G. Peracchia. “The effects of dietary factors, vitamins and trace elements in combination on PSA in young patients at risk for prostate cancer.” [In eng]. European Urology Supp 4, no. 3 (Mar 2005): 24.
Ostroumova, M. N., V. N. Anisimov, A. A. Syromiatnikov, and V. M. Dil’man. “[Decrease in the Excretion of Antigonadotropic Factor in Patients with Cancer of the Uterine Cervix and Prostate Gland. Experimental Antitumor Effect of an Epiphyseal Extract].” [In rus]. Vopr Onkol 22, no. 9 (1976): 39-43.
Nguyen, J. Y., J. M. Major, C. J. Knott, K. M. Freeman, T. M. Downs, and G. A. Saxe. “Adoption of a Plant-Based Diet by Patients with Recurrent Prostate Cancer.” [In eng]. Integr Cancer Ther 5, no. 3 (Sep 2006): 214-23.
Furuya, Y., K. Akakura, M. Masai, and H. Ito. “Vitamin D Receptor Gene Polymorphism in Japanese Patients with Prostate Cancer.” [In eng]. Endocr J 46, no. 3 (Jun 1999): 467-70.
Gaziano, J. M., R. J. Glynn, W. G. Christen, T. Kurth, C. Belanger, J. MacFadyen, V. Bubes, et al. “Vitamins E and C in the Prevention of Prostate and Total Cancer in Men: The Physicians’ Health Study Ii Randomized Controlled Trial.” [In eng]. JAMA 301, no. 1 (Jan 7 2009): 52-62.
Sumiyoshi, Y., K. Hashine, Y. Kakehi, K. Yoshimura, T. Satou, H. Kuruma, S. Namiki, and N. Shinohara. “Dietary Administration of Mushroom Mycelium Extracts in Patients with Early Stage Prostate Cancers Managed Expectantly: A Phase Ii Study.” [In eng]. Jpn J Clin Oncol 40, no. 10 (Oct 2010): 967-72.
New study expands look at effects of high-dose vitamin D with docetaxel for advanced prostate cancer patients.
“New Study Expands Look at Effects of High-Dose Vitamin D with Docetaxel for Advanced Prostate Cancer Patients.” [In eng]. Expert Rev Anticancer Ther 2, no. 5 (Oct 2002): 482-3.
Comparative analysis of vitamin A (retinol) regulated genes in African-American and caucasian prostate cancer patients.
Touma, S., L. Gudas, D. Nanus and S. Tickoo. “Comparative analysis of vitamin A (retinol) regulated genes in African-American and Caucasian prostate cancer patients.” [In eng]. Star Ed. 26:v.45, no. 23 (Nov 2007).
Surapaneni, K. M., and V. Ramana. “Erythrocyte Ascorbic Acid and Plasma Vitamin E Status in Patients with Carcinoma of Prostate.” [In eng]. Indian J Physiol Pharmacol 51, no. 2 (Apr-Jun 2007): 199-202.
Characteristics of TCR zeta chain expression in lymphocyte subsets of patients with androgen-independent prostate cancer in a phase 2 clinical trial with the vitamin D analog, 1-alpha-hydroxyvitamin D2.
Wilding, G., K. Tutsch, K. Schell, M. Pomplun, A. Dresen and H. Bailey. “Characteristics of TCR zeta chain expression in lymphocyte subsets of patients with androgen-independent prostate cancer in a phase 2 clinical trial with the vitamin D analog, 1-alpha-hydoxyvitamin D2.” [In eng]. Proceeedings of the Amer Assoc for Cancer Research Annual Meeting, no. 41 (Mar 2000): 43-44.
Beydoun, H. A., M. R. Shroff, R. Mohan, and M. A. Beydoun. “Associations of Serum Vitamin A and Carotenoid Levels with Markers of Prostate Cancer Detection among Us Men.” [In eng]. Cancer Causes Control 22, no. 11 (Nov 2011): 1483-95.
Ozmen, H., F. A. Erulas, F. Karatas, A. Cukurovali, and O. Yalcin. “Comparison of the Concentration of Trace Metals (Ni, Zn, Co, Cu and Se), Fe, Vitamins A, C and E, and Lipid Peroxidation in Patients with Prostate Cancer.” [In eng]. Clin Chem Lab Med 44, no. 2 (2006): 175-9.
Barnett, C. M., C. M. Nielson, J. Shannon, J. M. Chan, J. M. Shikany, D. C. Bauer, A. R. Hoffman, et al. “Serum 25-Oh Vitamin D Levels and Risk of Developing Prostate Cancer in Older Men.” [In eng]. Cancer Causes Control 21, no. 8 (Aug 2010): 1297-303.
Almushatat, A. S., D. Talwar, P. A. McArdle, C. Williamson, N. Sattar, D. S. O’Reilly, M. A. Underwood, and D. C. McMillan. “Vitamin Antioxidants, Lipid Peroxidation and the Systemic Inflammatory Response in Patients with Prostate Cancer.” [In eng]. Int J Cancer 118, no. 4 (Feb 15 2006): 1051-3.
Cryosurgery ablation of prostate as an alternative treatment in men affected by prostate cancer: Our experience in 56 patients.
Marronaro, A., G. Leone, E. Caraceni and A. Branchi. “Cryosurgery ablation of prostate as an alternative treatment in men affected by prostate cancer: Our experience in 56 patients.” [In eng]. European Urology Supplements 2, no. 1 (Feb 2003): 135.
Steginga, S. K., S. Occhipinti, R. A. Gardiner, J. Yaxley, and P. Heathcote. “A Prospective Study of the Use of Alternative Therapies by Men with Localized Prostate Cancer.” [In eng]. Patient Educ Couns 55, no. 1 (Oct 2004): 70-7.
Alternative therapies for advanced prostate cancer: What should I tell my patients?
Moyad, M. A. “Alternative Therapies for Advanced Prostate Cancer. What Should I Tell My Patients?” [In eng]. Urol Clin North Am 26, no. 2 (May 1999): 413-7, x.
ACP Journal Club. Vitamin E and vitamin C, alone or together, did not prevent prostate or total cancer in men.
Hoffman, R. M. “Acp Journal Club. Vitamin E and Vitamin C, Alone or Together, Did Not Prevent Prostate or Total Cancer in Men.” [In eng]. Ann Intern Med 150, no. 6 (Mar 17 2009): JC3-10, JC3-11.
Lehmann, D. “Hypokalaemic hypochloraemic metabolic alkalosis and hyponatraemia in a man with prostate cancer ingesting local plant extracts.” [In eng]. Drug Investigation 7, no. 3 (1994): 166-168.
Gilligan, T. and W. Oh. “Prospective trial of the herbal supplement PC-SPEC in patients with progressive prostate cancer: Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer: Commentary.’ [In eng]. Prostate J 3, no. 1 (2001): 44-45.
Association of vitamin D receptor-polymorphisms with prostate cancer in non-Hispanic white men.
Ingles, S. A., G. La Pera, M. C. Yu, R. W. Haile, R. K. Ross and G. A. Coetzee. “Association of vitamin D receptor-polymorphisms with prostate cancer in non-Hispanic white men.” [In eng]. Proceedings of the American Association for Cancer Research Annual Meeting 37 (1996): 259.
deVere White, R. W., A. Tsodikov, E. C. Stapp, S. E. Soares, H. Fujii, and R. M. Hackman. “Effects of a High Dose, Aglycone-Rich Soy Extract on Prostate-Specific Antigen and Serum Isoflavone Concentrations in Men with Localized Prostate Cancer.” [In eng]. Nutr Cancer 62, no. 8 (2010): 1036-43.
Corder, E. H., G. D. Friedman, J. H. Vogelman, and N. Orentreich. “Seasonal Variation in Vitamin D, Vitamin D-Binding Protein, and Dehydroepiandrosterone: Risk of Prostate Cancer in Black and White Men.” [In eng]. Cancer Epidemiol Biomarkers Prev 4, no. 6 (Sep 1995): 655-9.
Tayeb, M. T., C. Clark, N. E. Haites, L. Sharp, G. I. Murray, and H. L. McLeod. “Vitamin D Receptor, Her-2 Polymorphisms and Risk of Prostate Cancer in Men with Benign Prostate Hyperplasia.” [In eng]. Saudi Med J 25, no. 4 (Apr 2004): 447-51.
Oh, W. K., D. J. George, and P. W. Kantoff. “Rapid Rise of Serum Prostate Specific Antigen Levels after Discontinuation of the Herbal Therapy Pc-Spes in Patients with Advanced Prostate Carcinoma: Report of Four Cases.” [In eng]. Cancer 94, no. 3 (Feb 1 2002): 686-9.
Attitudes and use of alternative therapies in UK prostate cancer patients – Isn’t it time we were in the know?
Cheetham, P. J., K. J. Le Monnier, and S. F. Brewster. “Attitudes and Use of Alternative Therapies in Uk Prostate Cancer Patients-Isn’t It Time We Were in the Know?” [In Eng]. Prostate Cancer Prostatic Dis 4, no. 4 (2001): 235-41.
Moyad, M. A. “Complementary/Alternative Therapies for Reducing Hot Flashes in Prostate Cancer Patients: Reevaluating the Existing Indirect Data from Studies of Breast Cancer and Postmenopausal Women.” [In eng]. Urology 59, no. 4 Suppl 1 (Apr 2002): 20-33.
A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.
Fleming, C., J. H. Wasson, P. C. Albertsen, M. J. Barry, and J. E. Wennberg. “A Decision Analysis of Alternative Treatment Strategies for Clinically Localized Prostate Cancer. Prostate Patient Outcomes Research Team.” [In eng]. JAMA 269, no. 20 (May 26 1993): 2650-8.
Kolonel, L. N., J. H. Hankin, and C. N. Yoshizawa. “Vitamin A and Prostate Cancer in Elderly Men: Enhancement of Risk.” [In eng]. Cancer Res 47, no. 11 (Jun 1 1987): 2982-5.
deVere White, R. W., R. M. Hackman, S. E. Soares, L. A. Beckett, Y. Li, and B. Sun. “Effects of a Genistein-Rich Extract on Psa Levels in Men with a History of Prostate Cancer.” [In eng]. Urology 63, no. 2 (Feb 2004): 259-63.
Vitamin D receptor (VDR) gene Polymorphisms (Bsm1, Fok1, Cdx2) in total prostate cancer (CaP) risk among United States men.
Mikhak, B., D. Hunter, D. Spiegelman and E. Giovannucci. “Vitamin D receptor (VDR) gene Polymorphisms (Bsm1, Fok1, Cdx2) in total prostate cancer (CaP) risk among United States men.” [in eng]. Cancer Epidemiol Biomarkers Prev 13, no. 11, part 2 (Nov 2004): 1899S.
Rodriguez, C., E. J. Jacobs, A. M. Mondul, E. E. Calle, M. L. McCullough, and M. J. Thun. “Vitamin E Supplements and Risk of Prostate Cancer in U.S. Men.” [In eng]. Cancer Epidemiol Biomarkers Prev 13, no. 3 (Mar 2004): 378-82.
Osteoporosis and vitamin D deficiency in men with prostate carcinoma: Baseline results from a randomized prospective study.
Zietman, A., M. Smith, F. McGovern, P. Kantoff, N. Heney, J. Grocela, J. Finkelstein and M. Fallon. “Osteoporosis and vitamin D deficiency in men with prostate carcinoma: Baseline results from a randomized prospective study.” [In eng]. Cancer 88, no. 12 (Jun 2000): 3105-6.
Maistro, S., I. Snitcovsky, A. S. Sarkis, I. A. da Silva, and M. M. Brentani. “Vitamin D Receptor Polymorphisms and Prostate Cancer Risk in Brazilian Men.” [In eng]. Int J Biol Markers 19, no. 3 (Jul-Sep 2004): 245-9.
Serum levels of vitamin D metabolites and the subsequent risk of prostate cancer in Finnish men.
J. Tangrea, D. Albanes, O. Heinonen, P. Taylor and J. Virtamo. “Serum levels of vitamin D m etabolites and the subsequent risk of prostate cancer in Finnish men.” [In eng]. Proceeedings of the Amer Assoc for Cancer Research Annual Meeting 43 (Mar 2002): 932.
L. Meija, A. Sitova, R. Zeltite, D. Erdmane, R. Rafaels, U. Teibe, Lietuvietis and A. Lejnieks. “Vitamin D intake and deficiency in men at risk o prostate cancer.” [In eng]. Euro Urol Supp 9, no. 6 (Sep 2010): 536.
Chan, J. M., M. J. Stampfer, J. Ma, E. B. Rimm, W. C. Willett, and E. L. Giovannucci. “Supplemental Vitamin E Intake and Prostate Cancer Risk in a Large Cohort of Men in the United States.” [In eng]. Cancer Epidemiol Biomarkers Prev 8, no. 10 (Oct 1999): 893-9.
Hoenjet, K. M., P. C. Dagnelie, K. P. Delaere, N. E. Wijckmans, J. V. Zambon, and G. O. Oosterhof. “Effect of a Nutritional Supplement Containing Vitamin E, Selenium, Vitamin C and Coenzyme Q10 on Serum Psa in Patients with Hormonally Untreated Carcinoma of the Prostate: A Randomised Placebo-Controlled Study.” [In eng]. Eur Urol 47, no. 4 (Apr 2005): 433-9; discussion 39-40.
Durak, I., H. Biri, E. Devrim, S. Sozen, and A. Avci. “Aqueous Extract of Urtica Dioica Makes Significant Inhibition on Adenosine Deaminase Activity in Prostate Tissue from Patients with Prostate Cancer.” [In eng]. Cancer Biol Ther 3, no. 9 (Sep 2004): 855-7.
Sarkis, A. S., M. A. Nagai, S. Arap, and M. M. Brentani. “Molecular Characterisation and Racial Distribution of Androgen and Vitamin D Receptor Polymorphisms in Patients with Prostate Cancer, Benign Prostatic Hyperplasia and Age-Matched Healthy Controls.” [In Eng]. Prostate Cancer Prostatic Dis 2, no. S3 (Nov 1999): S30.
Collin, S. M., C. Metcalfe, H. Refsum, S. J. Lewis, G. D. Smith, A. Cox, M. Davis, et al. “Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer.” [In eng]. Cancer Epidemiol Biomarkers Prev 19, no. 11 (Nov 2010): 2833-8.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.